Financial Performance - Other income decreased by approximately RMB 13.3 million or 39.3% to about RMB 20.5 million for the year ending December 31, 2025[3]. - Other losses increased by approximately RMB 57.7 million or 488.7% to about RMB 69.5 million for the year ending December 31, 2025[3]. - Loss before tax increased by approximately RMB 44.5 million or 23.9% to about RMB 230.9 million for the year ending December 31, 2025[3]. - Total loss and comprehensive expenses increased by approximately RMB 43.6 million or 23.3% to about RMB 230.9 million for the year ending December 31, 2025[4]. - The company reported a net loss of RMB 230,907,000 for the year ended December 31, 2025, compared to a net loss of RMB 186,417,000 in 2024, representing a 23.8% increase in losses year-over-year[95]. - The company reported a pre-tax loss of RMB (230,907,000) in 2025, compared to RMB (186,417,000) in 2024[191]. - The company’s total equity attributable to owners was a negative RMB 13,927,000, compared to a negative RMB 13,296,000 in 2024, indicating a deterioration in equity position[100]. - The company incurred a loss per share based on the aforementioned data, reflecting ongoing financial challenges[197]. Research and Development - R&D expenses decreased by approximately RMB 21.4 million or 13.9% to about RMB 132.8 million for the year ending December 31, 2025[3]. - The company has established a comprehensive R&D structure from early development to commercialization, enabling rapid advancement of product development[15]. - The company has multiple TCR-T cell products in preclinical research targeting conditions such as renal clear cell carcinoma and viral infections like CMV and EBV[12]. - The core product EAL® has over ten years of clinical application experience and is focused on preventing postoperative recurrence of liver cancer, with plans to commercialize in China after achieving statistically significant clinical trial results[14]. - The company is advancing clinical research on CAR-T and TCR-T cell products, including ongoing Phase I and II clinical trials to achieve data compliance for market approval[32]. - The company has established a virus vector production system that meets GMP production quality standards, enabling large-scale production of viral vectors for CAR-T cell therapy[34]. - The company has completed the enrollment of 16 subjects in the Phase I clinical trial for Dinaroside injection[9]. - The company completed the enrollment of 430 subjects in the Phase II clinical trial for EAL®[5]. Clinical Trials - CAR-T-19 injection received breakthrough therapy designation for treating patients aged 25 and under with relapsed/refractory B-ALL[8]. - The company has completed the enrollment of six subjects in the Phase I clinical trial for 6B11-OCIK injection[6]. - The company completed the enrollment of 16 subjects in the Phase I clinical trial for Dinaroside injection[9]. - The 6B11-OCIK injection for ovarian cancer has completed the enrollment of six target subjects for its Phase I clinical trial, with plans to conduct Phase II trials based on business arrangements[19]. - The CAR-T-19 injection is designed for treating B-ALL in patients aged 25 and under, with the IND application accepted in August 2019 and Phase I trials initiated in December 2020[20]. - The aT19 injection, which aims to reactivate CAR-T cells and prevent recurrence of CD19 positive tumors, has received IND approval for its Phase I clinical trial, expected to commence in February 2024[23]. Financial Position and Liquidity - Bank balances and cash are projected to increase by RMB 7.5 million from RMB 47.0 million as of December 31, 2024, to RMB 54.5 million as of December 31, 2025, primarily due to the rights issue during the reporting period[50]. - As of December 31, 2025, lease liabilities are approximately RMB 103.4 million[51]. - The company has no outstanding debts, guarantees, or other significant contingent liabilities as of December 31, 2025[52]. - The company has bank balances and cash amounting to RMB 54,458,000 and structured bank deposits of RMB 100,109,000[109]. - The company is focused on improving liquidity and cash flow through various plans and measures[109]. - The current liquidity ratios show an increase, with the current ratio rising from 0.20 in 2024 to 0.35 in 2025, and the quick ratio increasing from 0.19 to 0.34 during the same period[62]. Cost Management - Administrative expenses decreased by approximately RMB 3.5 million or 7.9% to about RMB 41.0 million for the year ending December 31, 2025[3]. - The total employee compensation for the group was approximately RMB 56.9 million for the year, a decrease from RMB 70.1 million in 2024[74]. - The company’s total costs related to clinical trial subcontracting services included in R&D expenses were RMB 19,649 thousand, down from RMB 27,299 thousand, a decrease of approximately 28.2%[1]. - The company’s financial performance indicates a focus on cost reduction strategies amid ongoing losses[198]. Shareholder and Corporate Governance - The company has not declared or proposed any dividends during the reporting period[63]. - The company will hold its annual general meeting on May 22, 2026, with a record date for eligible shareholders set for the same day[66]. - The company has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions during the reporting period[68]. - The company has suspended share transfer registration from May 19 to May 22, 2026, to determine eligible shareholders for voting at the annual general meeting[67]. Government Support and Funding - The company is actively applying for government subsidies and believes it meets the criteria for local government support for its core R&D projects[111]. - The company has successfully obtained financial support from shareholders as needed[112]. - The company plans to invest approximately RMB 1.2 billion in the Beijing production center, with an expected annual production capacity exceeding 200,000 batches upon completion[28]. - The company raised a total of RMB 300 million from the issuance of convertible bonds, with RMB 102.3 million allocated for EAL® clinical trials and RMB 197.7 million for the construction of a new R&D and production center[56]. Employee Management - The company has implemented a performance evaluation system to determine employee salary adjustments, bonuses, or promotions, ensuring competitive compensation in the market[75]. - The company emphasizes employee training to enhance technical and product knowledge, offering tailored training programs for different positions[76]. - As of December 31, 2025, the total number of employees is 183, with 82 in production and supply chain, 50 in quality, 19 in management, and 16 in clinical support and business development[75].
永泰生物(06978) - 2025 - 年度业绩